Evidence map›Paper›PMID 37749033›Full record

Trial reportZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2023

[Efficacy and safety of bendamustine-rituximab combination therapy for newly diagnosed indolent B-cell non-Hodgkin's lymphoma and elderly mantle cell lymphoma: a multi-center prospective phase II clinical trial in China].

H Wang, Q He, D Liu, X Z Deng, J Ma, L N Xie, Z L Sun, C Liu, R R Zhao, K Lu and 10 more

Open access · greenAbstract readClinical Trial, Phase IIMulticenter StudyEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

H WangDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250000, China.
Q HeDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250000, China.
D LiuDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250000, China.
X Z DengDepartment of Hematology, Weihai Municipal Hospital, Weihai 264200, China.
J MaDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250000, China.
L N XieDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250000, China.
Z L SunDepartment of Hematology, Jining First People's Hospital, Jining 272000, China.
C LiuDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250000, China.
R R ZhaoDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250000, China.
K LuDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250000, China.
X X ChuDepartment of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, China.
N GaoDepartment of Hematology, Binzhou Medical University Hospital, Binzhou 256600, China.
H C WeiDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250000, China.
Y H SunDepartment of Hematology, Weifang People's Hospital, Weifang 261000, China.
Y P ZhongDepartment of Hematology, Qingdao Municipal Hospital, Qingdao 266000, China.
L J XingDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250000, China.
H Y ZhangDepartment of Hematology, Linyi People's Hospital, Linyi 276000, China.
H ZhangDepartment of Hematology, Affiliated Hospital of Jining Medical University, Jining 272000, China.
W W XuDepartment of Hematology, The First Affiliated Hospital of Shandong First Medical University, Jinan 250000, China.
Z J LiDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250000, China.
Qingdao University · CNWeifang People's Hospital · CNWeihai Municipal Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

LeukopeniaLymphoma, FollicularLymphoma, Mantle-CellAdultAgedBendamustine HydrochlorideChinaHumansMiddle AgedNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyProspective StudiesRituximabBendamustine HydrochlorideRituximabB cell indolent non-Hodgkin's lymphomaBendamustineMantle cell lymphomaRituximabTreatment

Identifiers

PMID37749033
PMCPMC10509620
OpenAlexW4387034051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.